This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2025 Oct 1;185(10):1217.

doi: 10.1001/jamainternmed.2025.3618.

Expanding the Evidence for Weight Loss Drugs in Diverse Populations

Ilana B Richman^{1

2}, Tracy Y Wang³

Affiliations

Affiliations

¹ Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
² Editorial Fellow, JAMA Internal Medicine.
³ Associate Editor, JAMA Internal Medicine.

PMID: 40758368
DOI: 10.1001/jamainternmed.2025.3618

Expanding the Evidence for Weight Loss Drugs in Diverse Populations

Ilana B Richman et al. JAMA Intern Med. 2025.

. 2025 Oct 1;185(10):1217.

doi: 10.1001/jamainternmed.2025.3618.

Authors

Ilana B Richman^{1

2}, Tracy Y Wang³

Affiliations

¹ Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
² Editorial Fellow, JAMA Internal Medicine.
³ Associate Editor, JAMA Internal Medicine.

PMID: 40758368
DOI: 10.1001/jamainternmed.2025.3618

No abstract available

PubMed Disclaimer

Comment in

Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial.
Kadowaki T, Heftdal LD, Ko HJ, Overvad M, Shimomura I, Thamattoor UK, Kim KK; OASIS 2 Investigators. Kadowaki T, et al. JAMA Intern Med. 2025 Oct 1;185(10):1206-1217. doi: 10.1001/jamainternmed.2025.3599. JAMA Intern Med. 2025. PMID: 40758358 Clinical Trial.

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems